White Blood Cell Count Shape Heart-Brain Coupling and rTMS Benefit in Depression

This study demonstrates that baseline white blood cell count moderates the relationship between heart-brain coupling during iTBS and clinical improvement in major depression, where higher coupling predicts symptom relief only in patients with lower inflammation, while elevated white blood cell counts are associated with specific white-matter microstructural alterations and reduced treatment efficacy.

The Gist

The Big Idea: Why the Same Treatment Doesn't Work for Everyone

Imagine you have a broken radio (your brain) that isn't playing music (you're depressed). You try to fix it by tapping a specific spot with a special hammer (a treatment called iTMS). Sometimes, the tapping works perfectly, and the music starts playing. Other times, the hammer hits, but nothing happens.

Scientists have always wondered: Why does the hammer work for some people but not others?

This study suggests the answer lies in your body's "background noise"—specifically, your inflammation.

The Characters in Our Story

1. The Hammer (iTMS): A non-invasive treatment that uses magnetic pulses to stimulate the brain. It's like a "reset button" for mood.
2. The Heart-Brain Dance (HBC): When the hammer hits the brain, a healthy brain responds by syncing up with the heart. It's like a dance where the heart and brain move in perfect rhythm. The researchers call this Heart-Brain Coupling.
   • The Theory: If the heart and brain dance well during the treatment, the patient gets better.
3. The Background Noise (Inflammation/WBC): This is the "dust" or "static" in your system. The researchers measured this by counting White Blood Cells (WBC).
   • Low WBC: The system is clean and quiet.
   • High WBC: The system is noisy, like a room full of construction workers.

The Discovery: The "Clean Room" Rule

The researchers tested a simple hypothesis: Does the "Heart-Brain Dance" only work if the room is quiet?

They found a surprising "Goldilocks" effect:

• Scenario A: The Quiet Room (Low Inflammation)
  If a patient has low white blood cell counts (a clean system), and their heart and brain start dancing together during the treatment, they get better. The treatment works like magic.

  • Analogy: It's like trying to hear a whisper in a library. If the room is quiet, the whisper (the treatment) is clear, and you understand it.

• Scenario B: The Noisy Room (High Inflammation)
  If a patient has high white blood cell counts (a noisy system), even if their heart and brain try to dance, the treatment doesn't work. The "dance" doesn't lead to improvement.

  • Analogy: It's like trying to hear that same whisper in a rock concert. Even if you are whispering perfectly, the noise (inflammation) drowns it out. The signal gets lost.

The "X-Ray" Proof (The Brain Scan)

To understand why the noisy room stops the treatment, the scientists looked inside the brain using a special MRI scan that measures "wetness" (Free Water).

• The Finding: People with high inflammation (High WBC) had "wet" or swollen pathways in their brain, specifically in the Fornix and Corpus Callosum.
• The Metaphor: Imagine the brain's communication cables are like fiber-optic wires. In the "noisy" group, these wires were soaked in water (edema/inflammation). This water makes the wires soggy and slow, so the electrical signal from the treatment can't travel fast enough to fix the problem. In the "clean" group, the wires were dry and crisp, allowing the signal to zip through instantly.

The Takeaway: A Simple Blood Test Could Save Time

The most exciting part of this study is that the "noise" level can be measured with a simple, cheap blood test (counting white blood cells).

• Before: Doctors might give the "hammer" treatment to everyone, hoping it works. If it fails, they have to try something else, wasting time and hope.
• After: Doctors can check the blood first.
  • If the count is low: "Great! Your brain is ready. Let's do the treatment. It will likely work."
  • If the count is high: "Hold on. Your system is too noisy for this treatment to work right now. Let's try to calm the inflammation first, then try the treatment later."

Summary in One Sentence

This study found that a brain stimulation treatment only works well if your body's inflammation is low; if your immune system is too "noisy," it blocks the brain from receiving the healing signal, but a simple blood test can tell us who is ready for treatment and who needs to wait.

Technical Summary

1. Problem Statement

Major Depressive Disorder (MDD) patients exhibit highly variable responses to repetitive transcranial magnetic stimulation (rTMS), specifically the intermittent theta burst stimulation (iTBS) protocol. Approximately 30% of MDD patients suffer from low-grade systemic inflammation, which is linked to poorer treatment outcomes, autonomic dysregulation, and increased cardiometabolic risk.

While Heart-Brain Coupling (HBC)—the synchronization of cardiac rhythms with stimulation trains—has been proposed as a physiological marker of vagal engagement and a predictor of iTBS efficacy, it remains unclear whether baseline immune status moderates this relationship. The study aims to determine if routine inflammatory markers (White Blood Cell count [WBC] and C-reactive protein [CRP]) act as moderators for the prognostic value of HBC and to investigate associated neuroimaging correlates (diffusion MRI free-water metrics).

2. Methodology

Study Design & Participants:

• Data Source: Secondary analysis of the PreNeSt2 study (NCT05260086), a randomized, quadruple-blind, sham-controlled crossover trial.
• Sample: 64 adults (18–60 years) with moderate-to-severe MDD.
• Exclusion: Participants with acute systemic inflammation at baseline (CRP > 10 mg/L or WBC > 11 × 10⁹/L) were excluded to focus on low-grade inflammation.
• Intervention: Participants received active or sham iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) for 3 weeks (pre-crossover period).

Key Measures:

• Inflammatory Markers: Baseline peripheral WBC and CRP (log-transformed due to skewness).
• Heart-Brain Coupling (HBC): Derived from ECG recordings during the first 2–4 iTBS sessions. HBC was quantified as the mean spectral power at 0.1 Hz, representing the alignment of heart rate dynamics with the stimulation pattern (a marker of vagal engagement).
• Clinical Outcome: Treatment response defined as ≥50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to Week 3.
• Neuroimaging: Diffusion MRI (DTI) was used to calculate Free-Water (FW) fractions, a marker of extracellular water content and neuroinflammation, using bi-tensor modeling in DSI Studio.

Statistical Analysis:

• Moderation Models: Separate logistic regression models tested whether WBC or CRP moderated the association between HBC and clinical response. Models included treatment allocation, mean-centered HBC, the inflammatory marker, and the interaction term (HBC × Inflammation).
• Robustness Checks: Bias-reduced (Firth) logistic regression and bootstrapping (BCa, 1,000 resamples) were used to address small-sample bias.
• Imaging Analysis: Connectometry was performed to correlate FW with inflammatory markers, stratifying participants by the Johnson-Neyman threshold derived from the moderation analysis.

3. Key Contributions

• Identification of a Biological Boundary Condition: The study establishes that baseline systemic inflammation (specifically WBC) acts as a critical moderator for the efficacy of HBC as a biomarker in iTBS.
• Differentiation of Inflammatory Markers: It demonstrates that WBC (reflecting cellular immune activity) is a more sensitive moderator of autonomic-neural coupling than CRP (an acute-phase hepatic protein) in the context of rTMS response.
• Structural Correlates: The study links peripheral immune tone to central microstructural alterations, specifically identifying increased free-water in limbic and interhemispheric white matter tracts (fornix, corpus callosum) in high-inflammation patients.
• Clinical Stratification Tool: It proposes a low-cost, routine clinical threshold (WBC ≈ 6.44 × 10⁹/L) to stratify patients who are likely to benefit from HBC-guided neuromodulation.

4. Results

Moderation of HBC by WBC:

• Significant Interaction: A significant interaction was found between HBC and WBC ($p = 0.008$).
  • Low WBC (< 6.44 × 10⁹/L): Higher HBC was strongly associated with clinical response (OR ≈ 3.35; AUC = 0.78). In this subgroup, HBC effectively distinguished responders from non-responders.
  • High WBC (≥ 6.44 × 10⁹/L): The predictive value of HBC disappeared (AUC ≈ 0.52, chance level). In fact, the association trended negative, suggesting high inflammation may negate the benefits of vagal engagement during stimulation.
• CRP Findings: CRP did not significantly moderate the HBC-response relationship ($p = 0.77$), suggesting WBC is the more relevant index for this specific mechanism.

Marginal Effects:

• Active stimulation increased response probability by ~25% on average.
• However, for every standard deviation increase in WBC, the likelihood of response decreased by ~9.3 percentage points.
• The benefit of HBC was significant only in the low-WBC subgroup (adding ~13.6 percentage points to response probability).

Neuroimaging (Free-Water) Findings:

• High-WBC Group: Showed significantly elevated Free-Water (FW) fractions compared to the low-WBC group.
• Affected Tracts: The elevation was most prominent in the fornix and corpus callosum (body, forceps major, tapetum), with secondary effects in the anterior thalamic radiation.
• Interpretation: Elevated FW suggests increased extracellular water content, consistent with neuroinflammation or vasogenic edema in circuits critical for affective and autonomic regulation.

5. Significance and Implications

Clinical Precision:
The study suggests that WBC is a practical, low-cost stratification marker for biomarker-guided neuromodulation. Clinicians can use routine blood work to identify patients with "low-grade inflammation" (WBC > 6.44 × 10⁹/L) who may not benefit from HBC as a predictor of response or who may require alternative treatment strategies (e.g., anti-inflammatory adjuncts) before or during rTMS.

Mechanistic Insight:
The findings support the vagal anti-inflammatory reflex hypothesis. The data suggests that high baseline inflammation (high WBC) may disrupt the frontal-vagal network (DLPFC to subgenual cingulate), preventing the effective engagement of the cholinergic anti-inflammatory pathway during iTBS. The observed white matter alterations (increased FW) in the fornix and corpus callosum provide a structural substrate for this disruption, linking peripheral immune status to central network integrity.

Future Directions:
This research highlights the need for longitudinal studies to determine if reducing inflammation (e.g., via lifestyle or pharmacological intervention) can restore HBC responsiveness in high-WBC patients. It also underscores the importance of integrating immune and autonomic measures to optimize the scalability and precision of depression treatments.

Limitations:

• The study used single-shell DTI, which offers less biological specificity than multi-shell acquisitions for free-water estimation.
• WBC was measured only at baseline; dynamic changes during treatment were not captured.
• The sample size for the high-WBC subgroup was relatively small, necessitating replication.